134 results about "Sulphated polysaccharides" patented technology

Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.

Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.

A method and medicament for treating inflammation in a patient with a sulfated polysaccharide without inducing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.

The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and/or a positively-charged polypeptide. Also, provided are delivery systems and methods for sustained release of said bioactive polypeptide(s) using said bioconjugates.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.

Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.

The present invention comprises bio-degradeable seed growth enhancer compositions that provide enhanced seed protection and propagation characteristics that can be formulated and tailored to the plant or crop species for best results. The formulations comprise a naturally - derived hydrophilic protein hydrogel with a sulfated or neutral non-sulfated polysaccharide incorporated therein together with an azeotropic drying agent. The drying agent is a preferably a low molecular weight alcohol or ketone which insures uniform application and adherence qualities of the coating when the hydrogel is dried onto the seed.

The present invention provides a multi-compartment hydrogel, and a sulfated polysaccharide and at least two bioactive polypeptides capable of binding said sulfated polysaccharide, for use in repair or regeneration of a damaged tissue in a mammal. Also provided is a method for constructing the multi-compartment hydrogel. The present invention also provides a method for the repair or regeneration of a damaged tissue in a mammal, and a kit for constructing a multi-compartment hydrogel.

A bio-degradable seed coating composition for enhanced seed protection and propagation consists of a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein, a sulfated or non-sulfated polysaccharide, a divalent cationic salt, and an azeotropic drying agent. The coating is readily applied to the seed and has enhanced drying functionality. The composition adheres to the seed surface and protects the seed during storage for improved shelf life while still being readily hydrated and water absorbent once planted in the respective growing medium.

The invention discloses a method for preparing a sulodexide raw material from a heparin byproduct by adopting an ethanol precipitation process. The method comprises the following steps: dissolving the heparin byproduct, adjusting a liquid to have a high pH value by sodium hydroxide, performing low-temperature precipitation by a proper amount of ethanol, and removing precipitate to obtain a sulphated polysaccharide liquid; adjusting the sulphated polysaccharide liquid to have a low pH value by hydrochloric acid, performing low-temperature precipitation by a proper amount of ethanol, and removing precipitate to obtain a sulphated polysaccharide liquid; and adjusting the liquid to be neutral by sodium hydroxide, performing room-temperature precipitation by a proper amount of ethanol, and drying precipitate to obtain the sulodexide raw material. The method is simple in process, low in cost, easy to realize and suitable for industrialized production.

Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.

The present invention concerns cohesive biopolymer gels comprising coprecipitates of sulfated polysaccharides and fibrillar proteins, exemplified by coprecipitates of dextran sulfate and gelatin, useful for clinical applications including as implants for tissue engineering as well as in biotechnology. The cohesive biopolymer gels according to the present invention may be used clinically either per se or as a scaffold for a cell-bearing implant, as a depot for sustained release of bioactive agents, or for research and biotechnology.

The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof.

The invention discloses a synthesis method of sulfated polysaccharide replaced by a non-primary hydroxyl group. A protecting group with a larger steric hindrance is used for protecting a primary hydroxyl group by the aid of a group protection technology, sulfated Artemisia stolonifera polysaccharide substituted by non-primary hydroxyl group is synthesized through regioselectivity, and the application range of the Artemisia sphoerocephala polysaccharide serving as a natural active material is enlarged. The substitution degree and the molecular weight of the sulfated Artemisia stolonifera polysaccharide substituted by non-primary hydroxyl group and prepared with the synthesis method can be optimized through proportional control of a sulfating reagent, and requirements of different areas are met. Besides, the synthesis method doesn't need special devices, and is simple, controllable and suitable for popularization and application.